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ail address: lusong@mednet.ucla.edu (L. Sona b s t r a c tObjectives: Immunoglobulin paraproteins can interfere with multiple chemistry assays.
We want to investigate the mechanisms of immunoglobulin interference.
Design and methods: Serum samples containing paraproteins from the index patient and
eight additional patients were used to investigate the interference with the creatinine and
total protein assays on the Beckman Coulter AU5400/2700 analyzer, and to determine the
effects of pH and ionic strength on the precipitation of different immunoglobulins in these
patient samples.
Results: The paraprotein interference with the creatinine and total protein assays was
caused by the precipitation of IgM paraprotein in the index patient's samples under al-
kaline assay conditions. At extremely high pH (12–13) and extremely low pH (1–2) and
low ionic strength, paraprotein formed large aggregates in samples from the index patient
but not from other patients.
Conclusions: The pH and ionic strength are the key factors that contribute to protein
aggregation and precipitation which interfere with the creatinine and total protein
measurements on AU5400/2700. The different amino acid sequence of each monoclonal
paraprotein will determine the pH and ionic strength at which the paraprotein will pre-
cipitate.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cases of monoclonal immunoglobulin (or ‘paraprotein’) interference with a wide variety of chemistry and im-
munochemistry tests on various automated chemistry or nephelometry (including turbidimetry) analyzers have been re-
ported. Besides a few systematic studies—such as paraprotein interference with the measurement of total and direct bi-
lirubin and high density lipoprotein cholesterol (HDL-C) on two automated chemistry analyzers using 88 samples with
paraproteins [1], and the study of interference with a direct bilirubin assay using 117 samples containing paraproteinsss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nge; AU2700, Beckman Coulter AU2700 analyzer; AU5400, Beckman Coulter AU5400 analyzer; CV,
C, high density lipoprotein cholesterol; IFE, immunofixation electrophoresis; IRB, Institutional Review
dium chloride; NaOH, sodium hydroxide; Cobas 8000, Roche Cobas 8000; SPEP, serum protein elec-
a
aboratory Medicine, University of California, Los Angeles, 757 Westwood Plaza, B403L, Los Angeles, CA
g).
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laboratory tests. There have been several reports of IgM paraprotein interference with albumin [3], glucose [4,5], C-reactive
protein [6], uric acid [7], HDL-C [8–10], total bilirubin [8,11], phosphate [5], creatinine [12–15], calcium [16], and total
protein [17–19]. Interestingly, each of these cases described individual IgM paraprotein interferences with a particular assay
on a particular platform. When other samples containing IgM paraproteins were tested with the same assay, the inter-
ferences were typically not observed. When the original samples were tested on different platforms, the interference may or
may not be observed [8,11,13–15]. In some reports, the interference was believed to be caused by the precipitation of
paraproteins under assay conditions [1,2,5,11]. We have encountered a case of a unique IgMκ paraprotein that exhibited
interferences with the creatinine, total protein, and direct bilirubin assays on the Beckman Coulter AU5400 (AU5400) and
AU2700 (AU2700) analyzers (Beckman Coulter, Brea, CA).
The patient was a 72 year-old male (index patient) who was referred to UCLA Medical Center for workup of his renal
insufficiency indicated by elevated serum creatinine levels which fluctuated between 1.5 and 3.2 mg/dL over a six month
period with an unrevealing renal ultrasound study. The initial laboratory evaluation at UCLA revealed an M-spike protein
(paraprotein) with a concentration of 3.4 g/dL by serum protein electrophoresis (SPEP) which was identified as IgMκ by
immunofixation electrophoresis (IFE). The index patient was diagnosed with Waldenström’s macroglobulinemia (WM)
supported by immunohistochemical and flow cytometric studies on a bone marrow biopsy sample. Thereafter, serum total
protein, creatinine, quantitative IgM, viscosity, and M-spike by SPEP were tested on a regular basis to follow the patient's
disease course. About three months after the presentation to our institution, a discrepancy in the patient's total protein
results was recognized by the clinical pathologist who was interpreting the patient's SPEP. A total protein result of 7.1 g/dL
was reported on the sample which had an albumin result of 3.0 g/dL and IgM concentration of 46.4 g/dL. This finding
triggered a laboratory investigation of the total protein and other chemistry tests performed on this sample which revealed
that the incorrect low total protein result of 7.1 g/dL was generated by the on-board dilution protocol. When the sample
(Sample 1A) was initially tested with AU5400, a total protein result of 10.2 g/dL was obtained which exceeded the upper
limit of the validated AMR of 10.0 g/dL. The instrument initiated the rerun with on-board dilution and obtained a result of
7.1 g/dL. This problem was recapitulated when the same sample was repeated on the AU2700 (the AU5400 and AU2700 use
the same chemistry assays) with an initial result of 10.2 g/dL and a rerun result of 7.2 g/dL obtained with the on-board
dilution. We also found the index patient's creatinine results puzzling, which in contrast to his previous elevated results
(both the method and platform are unknown to the authors), became undetectable (below the lower limit of detection) on
three occasions after being referred to our institution without having any treatment for renal infufficiency. The creatinine
result on Sample 1Awas cancelled due to technical difficulties to obtain a consistent result. Therefore, this study investigates
the causes of the interference with the creatinine and total protein assays on the AU5400/2700 and identifies the factors
that cause the IgM paraprotein to precipitate.2. Materials and methods
2.1. Patient specimens
Serum samples from the index patient (Subject 1) and randomly selected thirteen other patients (Subjects 2–14) were
used in this study. Nine samples from the index patient (Samples 1A–1I) collected from different times, and eleven samples
from eight additional patients who had elevated monoclonal IgM (Samples 2A, 2B, 3A, 3B, 3C, 5A–10A), three samples from
a patient with elevated biclonal IgMλ and IgMκ (Samples 4A, 4B, and 4C), a sample with elevated monoclonal IgG (Sample
11A), and a sample with polyclonal hypergammaglobulinemia (Sample 12A) were used in the studies of creatinine inter-
ference as well as the causes for protein precipitation. In addition, two samples (Samples 13A, and 14A) without elevated
immunoglobulins were used as controls for the studies. Note that both numbers and letters are used to name a sample with
the numbers denoting subjects and the letters denoting samples collected at different times. This study was performed
using de-identified and discarded samples that were obtained for patient care and not for the purpose of research;
therefore, Institutional Review Board (IRB) approval was not required.
2.2. Creatinine and total protein assays
Creatinine and total protein were measured on the AU5400/2700 analyzers and the Roche Cobas 8000 (Cobas 8000)
(Roche Diagnostics, Indianapolis, IN) respectively. The creatinine assay on the AU5400/2700 uses a modified kinetic Jaffé
method under alkaline conditions (pH around 12.7–12.9) and the result is determined by the rate of change of the absor-
bance at 520 nm. The creatinine reagent contains 120 mmol/L sodium hydroxide (NaOH), 2.9 mmol/L picric acid and some
unspecified preservatives in the final reaction. The order of addition for samples and reagents to the reaction cuvette is as
follows: 8 mL of the sample, 48 mL of the R1 reagent (containing NaOH), 36 mL of water, and 48 mL of the R2 reagent. The
analytical measurement range (AMR) of the creatinine assay is 0.2–25.0 mg/dL. The coefficient of variation (CV) is 0.8% at the
creatinine level of 0.93. The creatinine assay on the Cobas 8000 uses an enzymatic method performed under a less alkaline
condition (pH around 8.1) with an AMR of 0.06 to 30.5 mg/dL, and CV of 1.3% at the creatinine level of 1.0 mg/dL. Both the
AU5400/2700 and the Cobas 8000 use a biuret method for testing total proteins at alkaline conditions (pH around 12–13).
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sulfate, and 30 mmol/L potassium iodide in the final reaction. The order of addition for samples and reagents to the reaction
cuvette for the total protein assay on AU5400 is as follows: 5 mL of the sample, 33 mL of the R1 reagent (containing NaOH),
90 mL of water, and 33 mL of the R2 reagent. Our validated AMR is 0.2–10.0 g/dL. The CV is 0.5% at the protein level of 9.5 g/
dL.2.3. Other tests
IgM, IgG and IgA levels were determined by immunonephelometric methods on Siemens Dimension Vista 1500 (Siemens
Healthcare Diagnostics, Tarrytown, NY). SPEP and IFE were performed using the Sebia HYDRASIS 2 system (Sebia, Norcross,
GA). The concentration of M-spike was determined from the product of the relative intensity of the band of the protein in
the SPEP electrophoretogram and the concentration of total protein obtained with AU5400.2.4. Removing IgM paraproteins
Three samples from the index patient (Samples 1B, 1F, and 1H), one sample with IgMλ paraprotein (Sample 2A), and one
sample with normal immunoglobulins (Sample 13A) were used in this study. The average molecular weight of an IgM
molecule is 900 kDa [20]. Ultrafiltration using Amicon Ultra 100 K (100 kDa Molecular weight cutoff) Centrifugal Filters
(EMD Millipore, Merck KGaA, Darmstadt, Germany) at 5000 g for 20 min can remove IgM proteins and other proteins with
higher molecular weight from patient samples. Creatinine and total protein were measured with AU5400/2700 on these
samples before and after ultrafiltration.2.5. Experiments with pH and ionic strength
Solutions with pH ranging from 1 to 13 were prepared using either NaOH or hydrochloric acid (HCl) in deionized water.
Knowing that the first step of the creatinine assay on the AU5400 is the mixing of 8 μL of patient sample with 48 μL of the
R1 reagent, we manually performed this step in a 10-fold enlargement in test tubes by mixing 80 μL of patient sample with
either 480 μL of the R1 reagent or 480 μL of each of the pH solutions in order to observe the reaction. The R1 reagent of
creatinine assay contains NaOH which determines the pH of the reaction. We observed protein precipitates and/or ag-
gregates after addition of the R1 reagent, which did not re-dissolve in solution when water or the R2 reagent was added to
the mixture. Thus, the ratio of sample to pH solution (1:6) in these experiments was identical to the ratio of sample to R1
reagent (1:6) in the creatinine assay.
Solutions containing 0, 20, 40, 100, and 140 mM of sodium chloride (NaCl) at neutral pH (pH 7) were prepared. One of the
index patient's samples (Sample 1I), one sample with biclonal IgMλ and IgMκ (Sample 4C), and one sample without
paraprotein (Sample 13A) were used in this study. Eighty μL of patient sample was mixed with 480 μL of the NaCl solutions
(the same sample to reagent ratio of 1:6) in test tubes. The tubes were similarly examined to look for precipitates and/or
aggregates.Fig. 1. Ten replicate creatinine results for Sample 1B from the index patient obtained with the Beckman Coulter AU5400 (open circles) and the Roche Cobas
8000 (filled squares).
Table 1
Creatinine results obtained with the Beckman Coulter AU5400 in samples from the index patient and nine other patients.
Subjecta Sample IDb Time interval between
collectionsc
Type of paraprotein IgM concentration (mg/
dL)
Replicates of creatinine (mg/dL)
1 1A First IgMκ 7120 1.31 1.35 1.85
1B 199 days 4150 0.14 0.08 0.09
1C 34 days 4040 0.63 0.77 0.35
1D 0 day n.d. 0.41 0.72 0.73
1E 23 days n.d. 0.42 0.41 0.03
1F 46 days 4130 0.53 0.15 0.25
1G 0 day n.d. 0.01 2.00 0.56
1Hd 30 days 46400 0.09 2.61 5.35
0.34 2.50 0.02
2.38 0.78 0.91
2 2A First IgMλ 2150 0.70 0.67 0.68
2B 27 days 2410 0.77 0.75 0.75
3 3A First IgMκ 46400 1.35 1.38 1.34
3B 457 days 46400 1.51 1.45 1.45
3C 41 days 46400 1.75 1.84 1.80
4 4A First IgMκ and IgMλ 46400 1.85 1.67 1.70
4B 35 days 46400 1.62 1.83 1.79
4C 3 days 3890 1.67 1.60 1.57
5 5A First IgMκ 2250 1.51 1.45 1.40
6 6A First IgMκ 3320 1.26 1.28 1.45
7 7A First IgMκ 2180 1.21 1.21 1.20
8 8A First IgMκ 2340 0.89 0.91 0.92
9 9A First IgMλ 2030 0.84 0.79 0.78
12 12Ae First Polyclonal 170 10.50 10.20 10.40
n.d., not determined.
a Subject numbers denote different patients; Subject 1 is the index patient.
b Letters denote samples collected at different times from the same patient.
c Time interval between the collection of the sample and the collection of the previous sample; ‘First’ indicates the first sample encountered for each
patient by this study.
d Creatinine results were measured for a total of nine replicates for this sample.
e Patient had polyclonal hypergammaglobulinemia, IgG¼2200 mg/dL.
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3.1. IgM interference with the creatinine and total protein assays on the AU5400/2700
As a first approach to our investigation, we repeated creatinine measurement in duplicate with the AU2700 on Sample
1A and obtained values of 3.78 and 2.08 mg/dL, which was strikingly different than the previously reported undetectable
results obtained with the same instrument in our laboratory. Due to sample quantity constraints of Sample 1A, we used
another sample from the index patient (Sample 1B; IgM, 4150 mg/dL; viscosity, 2.19 cP; M-spike, 2.8 g/dL) collected 199 days
after Sample 1A and measured creatinine and total protein 10 times with both the AU2700 and the Cobas 8000, respectively.
The mean of the ten replicates of the total protein results on Sample 1B obtained with the initial protocol (undiluted) on
the AU2700 was 8.4 g/dL with a CV of 0.6%, similar to the mean of 8.86 g/dL and a CV of 2.5% obtained with the Cobas 8000.
The concordant total protein results between the AU2700 and the Cobas 8000 showed that the measurements of totalFig. 2. Nine replicate creatinine results obtained with AU5400 on sample 1H from the index patient.
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patient's sample. Therefore the interference was constrained to the on-board dilution for the total protein assay on the
AU5400/2700 analyzers.
The 10 replicates of creatinine results obtained with the AU5400 and Cobas 8000 are plotted in Fig. 1. The results with
AU5400 ranged from 0.18 to 0.39 mg/dL with a mean of 0.065 mg/dL and a CV of 340% which greatly exceeded the assay's
imprecision (CV of 16% at creatinine level of 0.05 mg/dL) and was in sharp contrast to the more consistent results obtained
with the Cobas 8000 (mean¼1.13 mg/dL, CV¼1.4%).
To determine if other IgM paraproteins would interfere with the Jaffé creatinine assay on the AU5400, we measured
creatinine in triplicate on 13 samples from 8 patients who had elevated monoclonal IgM immunoglobulins (Samples 2A–9A
in Table 1), one sample from a control patient who had polyclonal hypergammaglobulinemia (Sample 12A in Table 1), along
with 8 samples from the index patient (Samples 1A–1H in Table 1). Results are listed in Table 1 and the random fluctuating
creatinine results of Sample 1H from the index patient are plotted in Fig. 2. In contrast to the 8 samples from the index
patient, none of the other patient samples demonstrated fluctuating or spurious creatinine results. Therefore, the particular
IgM paraprotein in the index patient's sample appears unique in that it was the only one that interfered with the kinetic
Jaffé method on the AU5400/2700.
3.2. Precipitation of IgM paraprotein caused the interference
To better understand the mechanisms of the interference with the total protein and creatinine assays for the AU5400/
2700 in the index patient's sample (Sample 1A), both assays were performed in test tubes using 10-times more volume of
the sample and the respective reagents as that required by the assay reactions on AU5400. When 40 μL of Sample 1A was
mixed with 330 μL of the R1 reagent for the total protein assay, a large bulky protein aggregate was observed. Similarly,
large protein aggregates and tiny precipitates were observed when 80 μL of Sample 1A was mixed with 480 μL of the R1
reagent for the creatinine assay. These aggregates did not re-dissolve in solution when water and the R2 reagent of the
creatinine assay were added thereafter. Similar precipitates and aggregates were also observed when additional samples
from the index patient were tested. However, precipitates were not observed in control samples that had normal im-
munoglobulin levels. This indicates that the total protein and the creatinine assays of the AU5400 do not cause protein
precipitation in samples with normal immunoglobulin levels. It also provided evidence that the IgM paraprotein in the
index patient's samples aggregated and precipitated under the assay conditions.
Next, we determined if removal of IgM paraproteins from the index patient's sample using ultrafiltration would resolve
the interference with the AU5400/2700 creatinine assay. Table 2 lists creatinine and total protein results before and after
ultrafiltration measured with AU5400 on three samples from the index patient collected on different dates (Samples 1B, 1F,
and 1H), one sample from a patient with IgMλ paraprotein which did not interfere with the AU5400/2700 creatinine assay
(Sample 2A), and one control sample from a patient who did not have paraproteinemia (Sample 13A). In all of the samples,
total protein after ultrafiltration was reduced to 0.5 g/dL or less, indicating successful removal of IgM and other big proteins.
In the original samples of the index patient, the creatinine results were low but with marked random variation (0.81 to
0.18 mg/dL). The creatinine results after ultrafiltration were more consistent (0.92 to 1.01 mg/dL; Table 2) and similar to the
results obtained with the enzymatic method with Cobas 8000 (around 1.1 mg/dL). Creatinine results in the other two pa-
tient samples were not significantly affected by the removal of proteins (Table 2).
3.3. Effect of pH and ionic strength on the precipitation of paraproteins
The effect of pH on the formation of protein aggregates and/or precipitates was tested in one of the index patient’s
samples (Sample 1I), one sample with biclonal IgMλ and IgMκ paraproteins (Sample 4C), one sample with a monoclonal
IgMκ (Sample 10A), one sample with a monoclonal IgGκ (Sample 11A), and two samples without paraprotein (Samples 13ATable 2
Creatinine and total protein results obtained with the Beckman Coulter AU2700 on samples before and after ultrafiltration.
Sample IDa IgM (mg/dL) Creatinine (mg/dL) Protein (g/dL)
Original Filtrate Original Filtrate Original Filtrate
1Bb 4150 176 0.81 0.92 8.2 0.3
1F 4130 182 0.18 1.01 8.4 0.5
1H 46400 217 0.71 0.95 9.1 0.5
2Ac 2150 73 0.66 0.52 6.6 0.3
13Ad 308 o5 1.01 0.90 7.2 0.3
a Numbers in Sample ID denote individual patients and letters denote samples collected on different dates.
b Samples 1B, 1F and 1H were from the index patient.
c Patient had IgMλ paraprotein.
d Patient did not have paraproteinemia.
Table 3
Effect of pH on the precipitation of paraproteins.
Patient with IgMκ (index patient) Biclonal IgMκ, IgMλ IgMκ IgGκ No M-protein No M-protein
Sample IDa 1I 4C 10A 11A 13Ab 14Ab
IgM (mg/dL) 3940 3890 4130 132 308 179
IgG (mg/dL) n.d. n.d. 360 2840 521 944
pH 1 Aggregate Clear Clear Clear Clear Clear
pH 2 Aggregate Clear Clear Clear Clear Clear
pH 3 Tiny precipitates Tiny and large precipitates Clear Hazy Hazy Clear
pH 4 Tiny precipitates Clear Clear Clear Clear Hazy
pH 5 Tiny precipitates Clear Clear Clear Clear Clear
pH 6 Tiny precipitates Clear Clear Clear Clear Clear
pH 7 Tiny precipitates Clear Clear Clear Clear Clear
pH 8 Tiny precipitates Clear Clear Clear Clear Clear
pH 9 Tiny precipitates Clear Clear Clear Clear Clear
pH 10 Clear Clear Clear Clear Clear Clear
pH 11 Clear Clear Clear Clear Clear Clear
pH 12 Aggregate Clear Clear Clear Clear Clear
pH 13 Aggregate Clear Clear Clear Clear Clear
n.d., not determined.
a Numbers in Sample ID denote individual patients and letters denote samples collected on different dates.
b Patients did not have paraproteinemia.
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aggregates were observed at extremely alkaline pH (12–13) and extremely acidic pH (1–2) and tiny precipitates were ob-
served at pH 3–9. In Sample 4C, large and tiny protein precipitates were observed only at pH 3. In Sample 10A, no precipitate
was observed at any pH. In Sample 11A, except for a hazy appearance at pH 3, no precipitate was observed at any other pH.
Similarly, in normal control samples (Samples 13A and 14A), except for a hazy appearance at pH 3–4, no precipitate was
observed at any other pH. The results showed that the IgMκ paraprotein in the index patient's sample is unique and
different immunoglobulin paraproteins react to pH differently.
The effect of ionic strength on the precipitation of IgM paraproteins was studied using solutions with various con-
centrations of NaCl at neutral pH. The results of the ionic strength experiment are listed in Table 4. Tiny precipitates were
observed in the index patient's sample (Sample 1I) when added to solutions containing low concentrations of NaCl (0–
20 mM), but not in solutions containing higher concentrations of NaCl (higher than 40 mM). No precipitates were observed
in Sample 4C and Sample 13A at any of the concentrations of NaCl tested.4. Discussion
Herein, we present a case of a unique IgM paraprotein which interfered with the modified kinetic Jaffé creatinine and the
biuret total protein methods on the AU5400/2700 by forming large protein aggregates under assay conditions. The protein
aggregates/precipitates suspended in a solution can scatter light and interfere with the measurements of the absorbance.
Because the concentration of immunoglobulin paraprotein is generally high (7–65% of the total protein in serum), the
aggregation or precipitation of monoclonal immunoglobulins can change the physical–chemical properties such as turbidity
of the solution and cause significant alterations of the measurements of the transmitted or scattered light. If the precipitates
are small and evenly suspended in the solution, the errant light scattering may be corrected by background subtraction.
However, larger aggregates may not be corrected by background subtraction. The aggregates can randomly move in and out
of the light path causing a fluctuation pattern in the measured absorbance. This can be seen in the marked random fluc-
tuating pattern of the creatinine results obtained with the AU5400, as illustrated in Fig. 1. Fluctuating patterns in direct
bilirubin results obtained with the AU5400 associated with immunoglobulin paraprotein interference was also reported byTable 4
Effect of ionic strength on the precipitation of paraproteins.
Sample ID 1I 4C 13A
NaCl (mM) IgMκ (Index Patient) Biclonal IgMκ, IgMλ No M-spike
0 Aggregated Clear Clear
20 Aggregated Clear Clear
40 Clear Clear Clear
100 Clear Clear Clear
140 Clear Clear Clear
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erroneous results especially when the final result is determined from the difference between two measurement points such
as the kinetic Jaffé method for creatinine or between two reaction cuvettes such as the direct bilirubin method. Due to the
random light scattering by the large protein aggregates, the absorbance of an earlier measurement or of the blank can be
higher than the later measurement or of the reaction. In the kinetic Jaffé method for creatinine assay, the result is calculated
from the difference in absorbance measured at two predetermined time point. If the first absorbance exceeds the second
absorbance due to random light scattering of protein aggregates, not due to the colorimetric reaction itself, the result can be
negative. The direct bilirubin assay on AU5400 uses two cuvettes one for a blank and one for the reaction. If the absorbance
of the blank cuvette is higher than that of the reaction cuvette due to random light scattering of protein aggregate, the result
calculated from the difference between the two cuvettes can be negative. Therefore, an incorrect result with any value can
be obtained. Indeed, this would explain the spurious and fluctuating creatinine results including the negative ones obtained
in the index patient's samples in our experiments and the incorrect fluctuating results from his previous laboratory tests.
As for the index patient's IgM paraprotein interference with the total protein assay on AU5400, it appeared to happen
only to the on-board dilution protocol in which the instrument pipets 4 μL (instead of 5 μL) of a sample and mixes it with
the same amount of reagents as that used for the initial protein assay. The only difference between the initial protein assay
and the on-board dilution protocol is in the sample volume. We initially posited that the sample probe may not be capable
of accurately pipetting the smaller volume of sample when serum viscosity was highly elevated (4.58 cP, reference interval
1.10–1.80 cP). However this appears unlikely as the instrument can accurately pipet 1.5 μL of the same sample for the
albumin assay on the AU5400/2700. The initial total protein result of 10.2 g/dL was corroborated by duplicate measurements
with the Cobas 8000 which yielded results of 10.2 and 11.0 g/dL. We cannot explain why the problem was confined to the
on-board dilution protocol but speculate that the smaller sample volume happens to either speed up or slow down the
aggregation of IgM paraproteins in a way that alters the measurement of absorbance at the time point that is used to
determine the result.
Having noted that the pH of both of the total protein and creatinine assays are around 13, we speculated that it was the
high pH of these assays that caused the IgM paraprotein in the index patient's sample to precipitate. Thus, we tested and
obtained evidence that the extreme alkaline conditions (around pH 13) of both the creatinine and total protein assays of the
AU5400 caused the IgMκ paraprotein in the index patient's sample to form large aggregates. By adding the index patient's
sample to solutions with different pH at low ionic strength (NaCl was not added) in the same ratio as that of the sample to
the R1 reagent of the creatinine assay of the AU5400, we were able to demonstrate the formation of large protein aggregates
under extremely alkaline (pH 12–13) and extremely acidic (pH 1–2) conditions, as well as the formation of tiny precipitates
at pH 3–9. In addition, low ionic strength (0–20 mM NaCl) at neutral pH also caused this IgMκ paraprotein to precipitate. As
noted by Chi et al., pH has a strong influence on the rate of protein aggregation while ionic strength affects the stability of
protein conformation and alters protein solubility in aqueous solutions in a complex manner [21]. The index patient's IgM
paraprotein appears somewhat unique, as none of the other IgM paraproteins tested in this study demonstrated similar
problems with the creatinine or total protein assays on AU5400/2700. Our hypothesis is that this particular IgM protein
likely contains multiple opposite charged or polar amino acids such that at extremely high (pH 12–13) or low (pH 1–2) pH,
the protein is highly charged, leading to increased repulsions within the folded protein molecules that result in protein
unfolding which favors large protein aggregation through hydrophobic interactions. When pH is mildly increased or de-
creased (e.g. pH 3–9), the dipole-dipole interactions on the surface of the proteins in the absence of salt bridge could cause
the protein to aggregate [21]. The pH experiments in this study showed that the index patient's IgM paraprotein was soluble
only at pH 10–11 and otherwise insoluble over the remainder of the pH range tested, including pH 7.4. This appeared to be
contradictory to the notion that this IgM paraprotein was soluble in plasma at physiologic pH of 7.4. This is because the ionic
strength of our pH experiments was low (no NaCl was added), whereas the ionic strength is higher (140 mM NaCl) under
the physiologic conditions of plasma which functions as salt bridge to stabilize protein conformations and increase protein
solubility. We are unable to get the information related to the ionic strength of the creatinine and total protein assays on the
AU5400/2700. In this regard, we assumed the ionic strength is relatively low for both assays, which resulted in the de-
creased solubility of this particular IgM paraprotein under the assay conditions. The precipitation of monoclonal im-
munoglobulins under assay conditions is considered one of the mechanisms of paraprotein interference with chemistry
assays [22–26]. Our findings support the theory. Furthermore, we believe the precipitation of immunoglobulins is the main
cause for immunoglobulin interference with chemistry assays. The results of our study strongly suggest that assay pH and
low ionic strength are the two important factors which can induce protein precipitation that ultimately interferes with the
assay. Another example of paraprotein interference is the direct bilirubin assay on the AU5400/2700 which has a very low
pH (pH 1–2). We also observed interference in the direct bilirubin assay on the AU5400/2700 in the index patient's sample
and our pH experiment showed that this particular IgM paraprotein precipitated at pH 1–2. The immunoglobulin para-
protein interference with the direct bilirubin assay on AU5400/2700 has been investigated previously and the interference
rate was reported to be 17.1% in samples with monoclonal immunoglobulins [2]. Further review of the chemistry assays on
AU5400/AU2700 revealed that the pH for the creatinine (Jaffé method), total protein, and lithium assays are very alkaline
(pH 12–13), and for the direct bilirubin, phosphorous, and iron are very acidic (pH 1–2). The extreme pHs of these assays can
be used to explain why the majority of the reported cases of immunoglobulin paraprotein interference were associated with
these assays. Therefore, our pH experiments and these previous reports together support our conclusion that pH of
chemistry assays is a key factor for immunoglobulin interference.
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with biclonal IgMλ and IgMκ paraproteins (Sample 4C) did not precipitate at extremely high or low pH, but did so at pH 3.
The amino acid composition of each immunoglobulin determines the isoelectric point of the protein. Individual im-
munoglobulin paraproteins have unique amino acid sequences and thus different set points for conformational changes in
response to changes in pH and ionic strength. Thus, there is always a possibility that a particular immunoglobulin will
precipitate under a particular assay condition, whether basic or acidic, or even neutral pH. It would be very difficult to
condition an assay that will prevent all paraproteins from precipitation. Manufacturers should be aware of the possibility of
immunoglobulin paraprotein precipitation when they develop assays for clinical laboratories. For example, if a reaction must
be carried out at extremely high (or extremely low) pH, increasing the ionic strength or adding protein stabilizers or sur-
factants, provided that they do not significantly affect the test reactions, may help to prevent most paraproteins from
precipitating. In this regard, some manufacturers are aware the complex nature of the interference of immunoglobulin and
attempted to optimize their assays in order to minimize the problem of paraprotein precipitation [24]. This may partially
explain why the IgMκ paraprotein from the index patient presented in this study did not interfere with the total protein
assay on the Cobas 8000, which has an assay pH around 13 similar to that of the total protein assay on the AU5400/AU2700.
We believe that the majority of the chemistry assays are optimized in order to minimize the problem of paraprotein pre-
cipitation to certain degree by most of the manufacturers. That is why only a small percentage of paraprotein im-
munoglobulins, but not all of them, precipitate under a specific assay condition. Because assay conditions are likely to vary
on different platforms, a sample having problems with one method may not have the same problemwith a different method
or platform.
It is difficult for a clinical laboratory technologist working with an automated chemistry analyzer in a busy clinical
laboratory to know the presence of a paraprotein in a sample, unless being specifically alerted to its presence. It would be
very difficult for him or her to determine whether or not a result is valid and free from paraprotein interference. However,
understanding how paraproteins interfere with an assay will help to identify the problem. For example, a negative result, a
part of an analyte (such as direct bilirubin) is higher than the total concentration of the analyte (such as total bilirubin), or a
fluctuating pattern upon repeat measurements can serve as a flag. An inconsistent protein result between the direct and
diluted measurements can also serve as a flag. If the interference from monoclonal immunoglobulins is suspected, ultra-
filtration could be used to remove large proteins prior to certain assays that are not affected by removal of proteins, such as
creatinine as demonstrated in this study. Once the interference is identified, a different method or platform can be used and
the clinical team should be alerted. Recently, a new “abnormal reaction data-detecting” function on an automated chemistry
analyzer, BM2250 (supplied by JEOL Inc. in Japan, and ADVIA 2400 by Siemens Healthcare Diagnostics Inc. in other coun-
tries), has been tested and reported to be useful in detecting the abnormal turbidities caused by immunoglobulin pre-
cipitations [27]. If this new function does not significantly affect the throughput of the machine, it may help a clinical
laboratory to identify samples with paraproteins that interfere with chemistry assays.Acknowledgments
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